Humana Inc. (HUM) Q2 2025 Earnings Call Transcript

Humana Inc. (HUM) reported a strong Q2 2025, raising its full-year 2025 adjusted EPS outlook to approximately $17 from $16.25, primarily driven by better-than-expected performance from CenterWell Pharmacy and more resilient individual Medicare Advantage (MA) membership, which saw a lower decline than anticipated and a notable return of 'bounce back' members. Medical cost trends were in line with expectations, and the Medicaid business is performing as planned, mitigating broader industry challenges due to its product mix and state footprint. The company is actively streamlining operations, enhancing member experience through initiatives like simplified prior authorizations and an Epic MyChart integration, and remains confident in its operational progress for future Stars ratings despite ongoing litigation, while maintaining a prudent capital allocation strategy.

Analysis

Humana Inc. reported a strong second quarter, raising its full-year 2025 adjusted EPS guidance from approximately $16.25 to $17.00. This outperformance is primarily attributed to two key areas: the CenterWell Pharmacy segment, which benefited from higher direct-to-consumer volumes and favorable trends in Specialty Pharmacy, and a more resilient individual Medicare Advantage (MA) membership base. The company now anticipates an MA membership decline of up to 500,000, an improvement from the previously guided 550,000, supported by a significant number of "bounce back" members re-enrolling, who offer better year-one economics. Critically, medical cost trends, including inpatient utilization, are developing in line with expectations, with management reaffirming mid-to-high single-digit medical cost trend assumptions for 2026. The company's Medicaid business is also performing as planned, insulated from the broader industry pressures seen by peers due to a strategic focus on non-expansion states and long-term support services (LTSS) populations. Concurrently, Humana is executing a multi-year transformation focused on operational efficiency through an early retirement program and expanded outsourcing, while also investing an incremental $100 million to enhance member experience and operational excellence. While the Stars rating litigation has been refiled and the company is entering a quiet period ahead of CMS data in October, management remains confident in its operational progress to improve underlying metrics for future bonus years.

Key Decisions for Investors

• Investors should view the raised EPS guidance and resilient MA membership as evidence that Humana's strategy of repricing benefits over the past two years is successfully stabilizing its core book of business ahead of many competitors.
• Monitor the final CMS Stars ratings data in October and the outcome of the refiled litigation, as these are the most significant near-term catalysts that could materially impact the company's future earnings and margin recovery.
• Note the differentiated performance of the Medicaid segment and stable medical cost trends, which position Humana defensively against the headwinds currently impacting peers in the managed care sector.
• Consider the long-term value creation from the CenterWell segment, whose outperformance in specialty and direct-to-consumer pharmacy is providing a meaningful offset to MA market pressures and represents a key growth driver.